Holen Sie sich die Stockscreener-App
1.15
13.53%
-0.18
Handel nachbörslich:
1.15
Schlusskurs vom Vortag:
$1.33
Offen:
$1.28
24-Stunden-Volumen:
531.19K
Relative Volume:
0.11
Marktkapitalisierung:
$2.60M
Einnahmen:
$54.43M
Nettoeinkommen (Verlust:
$-36.70M
KGV:
-0.392
EPS:
-2.9334
Netto-Cashflow:
$-19.17M
1W Leistung:
-25.32%
1M Leistung:
+40.60%
6M Leistung:
+74.24%
1J Leistung:
-33.91%
1-Tages-Spanne:
$1.1151
$1.309
1-Wochen-Bereich:
$1.1151
$1.53
52-Wochen-Spanne:
$0.48
$3.44
Trinity Biotech Plc Adr Stock (TRIB) Company Profile
Firmenname
Trinity Biotech Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie TRIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRIB
Trinity Biotech Plc Adr
|
1.15 | 5.22M | 54.43M | -36.70M | -19.17M | -2.9334 |
|
ABT
Abbott Laboratories
|
132.81 | 228.80B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.29 | 158.04B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.34 | 149.08B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.85 | 119.71B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
80.96 | 48.01B | 5.69B | 1.41B | 577.90M | 6.95 |
Trinity Biotech Plc Adr Stock (TRIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2015-10-23 | Herabstufung | Craig Hallum | Buy → Hold |
| 2015-09-03 | Eingeleitet | Raymond James | Outperform |
| 2015-07-29 | Bestätigt | ROTH Capital | Buy |
| 2008-07-22 | Bestätigt | Roth Capital | Buy |
| 2008-03-17 | Bestätigt | Roth Capital | Buy |
| 2007-12-10 | Bestätigt | Roth Capital | Buy |
| 2007-10-26 | Bestätigt | Roth Capital | Buy |
Alle ansehen
Trinity Biotech Plc Adr Aktie (TRIB) Neueste Nachrichten
TRINITY B ADR : Trinity Biotech plc to Present at Sidoti & Company's Micro-Cap Conference on January 10, 2011 - MarketScreener
Trinity Biotech plc Appoints Paul Tivnan as Non-Executive Director - MarketScreener
Trinity Biotech appoints Paul Tivnan to board of directors - Investing.com
Trinity Biotech Appoints Paul Tivnan as Non-Executive Director - MarketScreener
Trinity Biotech receives approval for offshore manufacturing of HIV test - Investing.com
Regulatory Approval Granted for Commencement of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation - MarketScreener
TRIB’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Trinity Biotech stock soars after NY regulatory approval for preeclampsia test By Investing.com - Investing.com South Africa
Trinity Biotech stock soars after NY regulatory approval for preeclampsia test - Investing.com India
Trinity Biotech receives NY approval for preeclampsia test - Investing.com
Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service - GlobeNewswire Inc.
Trinity Biotech stock rises on successful CGM calibration-free trial By Investing.com - Investing.com South Africa
Trinity Biotech stock rises on successful CGM calibration-free trial - Investing.com India
Trinity Biotech reports positive results for calibration-free CGM By Investing.com - Investing.com South Africa
Trinity Biotech reports positive results for calibration-free CGM - Investing.com India
Trinity Biotech (TRIB) to Release Earnings on Wednesday - Defense World
Trinity Biotech launches preeclampsia testing service for maternal health By Investing.com - Investing.com South Africa
Trinity Biotech launches preeclampsia testing service for maternal health - Investing.com India
Trinity Biotech Plc Sponsored ADR Class A to Host Earnings Call - ACCESS Newswire
Cadence Bank (CADE) Stock: A Year of Market Fluctuations - investchronicle.com
Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround - MarketScreener
Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic and Financial Performance Transformation - MarketScreener
Trinity Biotech receives WHO approval for offshore HIV test manufacturing - Investing.com
Trinity Biotech Appoints New Interim CFO - Investing.com India
Trinity Biotech stock hits 52-week low at $0.62 amid challenges - Investing.com
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process - MarketScreener
Trinity Biotech (NASDAQ:TRIB) Research Coverage Started at StockNews.com - Armenian Reporter
Trinity Biotech stock hits 52-week low at $0.72 amid challenges - Investing.com
Trinity Biotech secures $4m for CGM technology growth - Investing.com
Trinity Biotech secures amended credit to fuel growth - Investing.com
Investor Network: Trinity Biotech Plc Sponsored ADR to Host Earnings Call - ACCESS Newswire
Trinity Biotech stock hits 52-week low at $0.74 amid market challenges - Investing.com
Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial - MarketScreener
Trinity Biotech secures US funding for HIV tests - Investing.com
Trinity Biotech faces US aid policy impact, PPP loan scrutiny - Investing.com
Trinity Biotech announces breakthrough in CGM technology - Investing.com
Trinity Biotech Expands Market Reach with New ADS Offering - Nasdaq
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan - MarketScreener
Trinity Biotech plc Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV - MarketScreener
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements - MarketScreener
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture - MarketScreener
Trinity Biotech : Announces Positive Pre Pivotal Trial Results for Its Next Generation Continuous Glucose Monitor Technology Form 6 K - MarketScreener
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market - MarketScreener
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer - MarketScreener
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology - MarketScreener
Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director - MarketScreener
Trinity Biotech Announces Appointment of A New CFO - MarketScreener
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association - MarketScreener
Trinity Biotech Announces the Appointment of Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development - MarketScreener
Trinity Biotech to Implement ADS Ratio Change By Investing.com - Investing.com India
Trinity Biotech Announces CE Mark of its Covid-19 IgG Elisa Antibody Test - MarketScreener
Finanzdaten der Trinity Biotech Plc Adr-Aktie (TRIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):